Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives.

Autor:	Yu Z; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China., Zhou X; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, China.; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, China.; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China., Wang X; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, China.; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, China.; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2022 Sep 02; Vol. 82 (17), pp. 2955-2963.
DOI:	10.1158/0008-5472.CAN-22-0917
Abstrakt:	Metabolic reprogramming is a hallmark of cancer progression. Metabolic activity supports tumorigenesis and tumor progression, allowing cells to uptake essential nutrients from the environment and use the nutrients to maintain viability and support proliferation. The metabolic pathways of malignant cells are altered to accommodate increased demand for energy, reducing equivalents, and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, which can lead to tumorigenesis when abnormalities accumulate. Clinical and preclinical studies have shown that targeting metabolic features of hematologic malignancies is an appealing therapeutic approach. This review provides a comprehensive overview of the mechanisms of metabolic reprogramming in hematologic malignancies and potential therapeutic strategies to target cancer metabolism. (©2022 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu